ProQR Therapeutics N.V. Ordinary Shares (PRQR)

Price$1.42

Value ScoreC

Growth ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-39.23%

Price vs S&P 500 (4W)-3.04%

VGM Score41.38

Market Capitalization$187.24M

All Metrics

Book Value / Share (Quarterly)$0.41

P/TBV (Annual)5.67x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)50.45%

Cash Flow / Share (Quarterly)$-0.53

Price vs S&P 500 (YTD)-32.72%

Net Profit Margin (TTM)-333.51%

EPS (TTM)$-0.50

10-Day Avg Trading Volume0.54M

EPS Excl Extra (TTM)$-0.50

Revenue Growth (5Y)11.58%

EPS (Annual)$-0.47

ROI (Annual)-64.56%

Net Profit Margin (5Y Avg)-923.85%

Cash / Share (Quarterly)$0.88

Revenue Growth QoQ (YoY)-57.12%

ROA (Last FY)-37.41%

Revenue Growth TTM (YoY)-30.51%

EBITD / Share (TTM)$-0.48

ROE (5Y Avg)-67.66%

Operating Margin (TTM)-339.31%

Cash Flow / Share (Annual)$-0.58

P/B Ratio3.67x

P/B Ratio (Quarterly)3.90x

Net Income / Employee (Annual)$-262,897

EV / Revenue (TTM)5.32x

Net Interest Coverage (TTM)-13.09x

ROA (TTM)-38.41%

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)3.09x

Quick Ratio (Quarterly)2.39x

3-Month Avg Trading Volume0.52M

52-Week Price Return-9.20%

Revenue / Employee (TTM)$84,952

Tangible BV / Share (Quarterly)$2.51

P/S Ratio (Annual)8.44x

Asset Turnover (Annual)0.14x

52-Week High$3.10

Operating Margin (5Y Avg)-899.36%

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)2.09%

Tangible BV CAGR (5Y)10.74%

26-Week Price Return-23.30%

Quick Ratio (Annual)3.01x

13-Week Price Return-0.63%

Total Debt / Equity (Annual)0.32x

Current Ratio (Quarterly)2.48x

Enterprise Value$84.60M

Revenue / Share Growth (5Y)-3.84%

Asset Turnover (TTM)0.12x

Book Value / Share Growth (5Y)-15.36%

Revenue / Employee (Annual)$101,849

Pretax Margin (Annual)-257.94%

Cash / Share (Annual)$1.00

3-Month Return Std Dev81.19%

Net Income / Employee (TTM)$-283,523

ROE (Last FY)-85.44%

Net Interest Coverage (Annual)-21.33x

EPS Basic Excl Extra (Annual)$-0.47

P/FCF (TTM)13.26x

Receivables Turnover (TTM)27.17x

Total Debt / Equity (Quarterly)0.42x

EPS Incl Extra (TTM)$-0.50

Receivables Turnover (Annual)0.17x

ROI (TTM)-65.91%

P/S Ratio (TTM)10.11x

Pretax Margin (5Y Avg)-921.60%

Revenue / Share (Annual)$0.18

Tangible BV / Share (Annual)$2.51

Price vs S&P 500 (52W)-37.40%

Year-to-Date Return-21.78%

5-Day Price Return1.28%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-28.35%

Net Profit Margin (Annual)-258.05%

Month-to-Date Return0.64%

Cash Flow / Share (TTM)$-0.50

EBITD / Share (Annual)$-0.45

Operating Margin (Annual)-265.77%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-49.32%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.50

P/TBV (Quarterly)5.67x

P/B Ratio (Annual)3.70x

Pretax Margin (TTM)-333.37%

Book Value / Share (Annual)$0.53

Price vs S&P 500 (13W)-10.38%

Beta0.02x

P/FCF (Annual)6.84x

Revenue / Share (TTM)$0.15

ROE (TTM)-86.22%

52-Week Low$1.33

vGradeC

gGradeD

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.15est. -0.14

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRQRProQR Therapeutics N.V. Ordinary Shares	C	D	C	$1.42
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

ProQR Therapeutics NV develops RNA-based therapeutics for severe genetic rare diseases, including cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The company's entire research and development effort is dedicated to discovering and advancing RNA therapeutics.